Cullinan reports initial Phase 1 data for CLN-978: B cell depletion and early efficacy in RA/SLE

Cullinan Therapeutics, Inc.

As of Jan 14, 2026 cutoff, 14 patients dosed (5 RA, 9 SLE) across cohorts 1-3.
B cell depletion >75% in 9/11 patients after 10 mcg; 3/6 below quantification after 20 mcg.
4/5 RA patients had DAS28-ESR decrease from high activity to moderate/remission.
5/6 SLE patients had SLEDAI score decrease >4 points; ultrasound synovitis improved in 3/4 RA.
CLN-978 well tolerated; dose escalation continues; updated data at EULAR June 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.